Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.

@article{Subbiah2012TargetingTA,
  title={Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.},
  author={Vivek Subbiah and Robert G. Brown and Jamie Jay Buryanek and Jonathan C. Trent and Avi Ashkenazi and Roy S. Herbst and Razelle Kurzrock},
  journal={Molecular cancer therapeutics},
  year={2012},
  volume={11 11},
  pages={2541-6}
}
Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1-5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter… CONTINUE READING
20 Citations
27 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine

  • RE Brown
  • Arch Pathol Lab Med
  • 2009
2 Excerpts

Similar Papers

Loading similar papers…